HXQYF mainly consists of flavonoid components (quercetin, kaempferol, isorhamnetin), terpenoid (Ginkgolide A), and paeoniflorin, which have been confirmed potential for treating NAFLD via reducing the hepatic lipid accumulation, causing mitochondrial oxidative stress, inhibiting de novo lipid synthesis, and regulating the ROCK/IRS/Akt signaling pathways [57–59]. This evidence concerns the gene IARS1 and metabolic dysfunction-associated steatotic liver disease.